ABZENA Inside Products - Abzena

ABZENA Inside

Abzena has over 40 technology licence and option agreements covering its proprietary antibody drug conjugate (ADC) linker, antibody humanisation, and protein deimmunisation technologies. The linker technology produces more stable and homogenous ADCs and the humanisation and deimmunisation technologies reduce the risk of therapeutic antibodies and other proteins producing an unwanted effect in patients. There are currently twelve therapeutic antibodies produced using Abzena’s antibody humanisation technology being progressed through clinical development by its partners. Abzena has the potential to earn license fees, milestone payments and/or royalties on these products.

Interested in our services? Get In Touch